Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12N2O2 |
| Molecular Weight | 240.2573 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=NC=C2NC3=CC=CC=C3C2=C1
InChI
InChIKey=KOVRZNUMIKACTB-UHFFFAOYSA-N
InChI=1S/C14H12N2O2/c1-2-18-14(17)12-7-10-9-5-3-4-6-11(9)16-13(10)8-15-12/h3-8,16H,2H2,1H3
Ethyl β-carboline-3-carboxylate or beta-carboline-3-carboxylic acid ethyl ester, an endogenous compound that was isolated from human urine. It is a partial inverse agonist at the benzodiazepine site on the GABA-A receptor. Experiments on rats have shown that ethyl β-carboline-3-carboxylate produces the anxiogenic-like effect but do not affect brainstem activated hippocampal theta.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3005790 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Relative potency and effectiveness of flunitrazepam, ethanol, and beta-CCE for disrupting the acquisition and retention of response sequences in rats. | 2009-02 |
|
| Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls. | 1988 |
|
| Discriminative and aversive properties of beta-carboline-3-carboxylic acid ethyl ester, a benzodiazepine receptor inverse agonist, in rhesus monkeys. | 1986-03-17 |
|
| Interactions between the benzodiazepine receptor antagonist Ro 15-1788 (flumazepil) and the inverse agonist beta-CCE: behavioral studies with squirrel monkeys. | 1985-04-08 |
|
| beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic acid. | 1983-04 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19179849
in rats: 1-17.8 mg/kg. Injections for drug was administered i.p. 15 min before the start of the session or 15 min before the retention test.
Route of Administration:
Intraperitoneal
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m5104
Created by
admin on Mon Mar 31 21:22:10 GMT 2025 , Edited by admin on Mon Mar 31 21:22:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID70225208
Created by
admin on Mon Mar 31 21:22:10 GMT 2025 , Edited by admin on Mon Mar 31 21:22:10 GMT 2025
|
PRIMARY | |||
|
610937
Created by
admin on Mon Mar 31 21:22:10 GMT 2025 , Edited by admin on Mon Mar 31 21:22:10 GMT 2025
|
PRIMARY | |||
|
HYW8K5N21Y
Created by
admin on Mon Mar 31 21:22:10 GMT 2025 , Edited by admin on Mon Mar 31 21:22:10 GMT 2025
|
PRIMARY | |||
|
105078
Created by
admin on Mon Mar 31 21:22:10 GMT 2025 , Edited by admin on Mon Mar 31 21:22:10 GMT 2025
|
PRIMARY | |||
|
74214-62-3
Created by
admin on Mon Mar 31 21:22:10 GMT 2025 , Edited by admin on Mon Mar 31 21:22:10 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD